Search Results: (30 results)

Interview with Latino/a parents to share their experiences about their child's genetic care

We want to learn about your experience with genetic testing and the healthcare providers you worked with, such as genetic counselors and oncologists.

This study is testing two different vaccine-based treatment approaches combined with immunotherapy for people with pancreatic cancer that can be removed with surgery

Researchers are conducting a study to better understand how people make important health decisions and how they feel about those decisions over time. The goal of this study is to learn what factors help patients feel confident and satisfied with their health-related decisions, as well as what may lead to regret or uncertainty later on.

Research study on how couples’ experience with cancer-related financial challenges affects their health and relationship.

This study is testing an experimental vaccine that helps the immune system recognize changes in a protein called KRAS, which is commonly involved in pancreatic cancer. The vaccine is given with an immune-boosting medicine that helps improve the body’s response.

The purpose of this study is to understand knowledge and opinions about pancreatic cancer screening, access to and decision-making around screening, and how a blood-based test might influence screening among individuals with inherited (germline) mutations associated with increased pancreatic cancer risk, including APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53. 

This is a long-term observational study designed to improve early detection and prevention of ovarian and other gynecologic cancers.

This study is testing whether a new targeted therapy called AZD5335 works better than currently used treatments for people with platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer.The study is looking at how long people live without their cancer getting worse while taking AZD5335 compared with standard treatments. 

This study is testing a personalized cancer vaccine designed using proteins (called neoantigens) taken directly from a person’s tumor.

This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor DNA (ctDNA), tiny pieces of cancer DNA that may be present in the bloodstream. Researchers want to learn how well this test can:

• Detect cancer recurrence early
• Predict outcomes after treatment
• Support future use of blood‑based monitoring instead of—or in addition to—imaging tests

This clinical trial is testing whether two targeted cancer drugs taken together work better than one drug alone for treating advanced endometrial cancer that has come back or did not respond to prior treatment. To be eligible, the cancer must test positive for a biomarker known as a RAS pathway mutation.

This study is evaluating whether a surgical support mesh called GalaFLEX LITE™ Scaffold can improve outcomes for women undergoing revision breast implant surgery due to complications such as capsular contracture (hardening of scar tissue around the implant).

This research study is enrolling prostate cancer patients who plan to undergo surgery to have their prostate removed (radical prostatectomy) and whose cancer has one of the listed gene mutations: ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA or BRIP1.

This study is looking at whether a menstrual cup can be used as a simple, non-invasive way to collect menstrual blood for detection of endometrial (uterine) cancer earlier—especially in people with Lynch syndrome or others at high risk.

This study collects health information and DNA samples such as blood or saliva from participants to help researchers better understand cancer risk and early detection.

Genetic risk screening and genetic testing study for Black/African American adults ages 18 and older in the Houston, Texas area.

This phase II study is testing low-dose tamoxifen, with or without high-dose omega-3 fatty acids, in postmenopausal women who are overweight or obese and at increased risk for breast cancer.

Online survey recruiting participants who reside in the United States, have been diagnosed with cancer, and are 18 years or older.

This study is testing whether a new targeted drug called puxitatug samrotecan (Puxi-Sam) works better than standard chemotherapy for treating advanced or metastatic endometrial cancer whose cancer has grown or returned after prior treatment with platinum chemotherapy and immunotherapy. 

This study is looking at how well an experimental blood test works for finding cancer earlier in people who have a higher-than-average risk of cancer because of an inherited mutation. Note: This study is only open in Canada. 

This study is testing whether combining a new type of targeted drug called RAS(ON) inhibitors with an immunotherapy drug called ivonescimab is safe and may help slow or shrink cancer in people with advanced or metastatic solid tumors that have a biomarker called a RAS mutation.

This study is to characterize the lived experiences of people who do not have a history of cancer after learning they have a BRCA mutation.

This study is testing a new approach to help people with different types of advanced cancer cope with fear about their cancer getting worse. The study will compare whether a short series of guided writing sessions delivered by telehealth works better than usual supportive care. 

Study to understand how people with inherited CDH1 or CTNNA1 mutations perceive their risk of gastric (stomach) cancer and their attitudes toward endoscopic surveillance and other medical options.

This study is testing two new investigational targeted drugs called RAS(ON) inhibitors alone or in combination with each other to learn how safe they are and how well they may work in people with advanced or metastatic solid tumors that have a biomarker called a KRAS G12C mutation.

This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.

This study is testing a new treatment that combines a KRAS-targeted cancer vaccine (ELI-002) with two immunotherapy drugs (balstilimab and botensilimab) in people with advanced colorectal or pancreatic cancers with a KRAS tumor mutation and a marker known as mismatch repair proficiency (pMMR or MMR-p).

This study is testing palazestrant (also called OP-1250), an investigational medicine, for people with estrogen receptor-positive (ER-positive), HER2-negative advanced or metastatic breast cancer.

This study is looking at whether removal of the fallopian tubes (salpingectomy) followed by removal of the ovaries (oophorectomy) at a later date closer to the time of natural menopause may reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes at the same time (salpingo-oophorectomy) among women with an inherited BRCA1, BRCA2, BRIP1, RAD51C or RAD51D mutation. Removing the fallopian tubes only first and the ovaries at a later time closer to natural menopause may lessen menopausal symptoms while still lowering the risk for ovarian cancer.